NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE49423 Query DataSets for GSE49423
Status Public on Aug 01, 2013
Title Acute Genome-Wide Effects of Rosiglitazone on PPARγ Transcriptional Networks in Adipocytes
Organism Mus musculus
Experiment type Genome binding/occupancy profiling by high throughput sequencing
Summary Here we report, for the first time, the acute effects of the synthetic PPARγ agonist rosiglitazone on the transcriptional network of PPARγ in adipocytes. Treatment with Rosiglitazone for 1 hour leads to acute transcriptional activation as well as repression of a number of genes as determined by genome-wide RNA polymerase II occupancy. Unlike what has been shown for many other nuclear receptors, agonist treatment does not lead to major changes in the occurrence of PPARγ binding sites. However, rosiglitazone promotes PPARγ occupancy at many preexisting sites, and this is paralleled by increased occupancy of the mediator subunit MED1. The increase in PPARγ and MED1 binding is correlated with an increase in transcription of nearby genes indicating that rosiglitazone, in addition to activating the receptor, also promotes its association with DNA, and that this is causally linked to recruitment of mediator and activation of genes. Notably, both Rosiglitazone-activated and -repressed genes are induced during adipogenesis. However, Rosiglitazone-activated genes are markedly more associated with PPARγ than repressed genes and are highly dependent on PPARγ for expression in adipocytes. By contrast, repressed genes are associated with the other key adipocyte transcription factor CCAAT-Enhancer binding protein (C/EBPα), and their expression is more dependent on C/EBPα. This suggests that the relative occupancies of PPARγ and C/EBPα are critical for whether genes will be induced or repressed by PPARγ agonist.
 
Overall design Examination of binding of PPARγ, C/EBPα, RNAPII, CBP and MED1 in mature 3T3-L1 adipocytes treated with 1 μM Rosiglitazone and/or 0.1% DMSO for 1 hour.
 
Contributor(s) Haakonsson AK, Madsen MS, Nielsen R, Sandelin A, Mandrup S
Citation(s) 23885096
Submission date Jul 31, 2013
Last update date May 15, 2019
Contact name Susanne Mandrup
E-mail(s) s.mandrup@bmb.sdu.dk
Phone +45 6550 2340
Organization name University of Southern Denmark
Department Biochemistry and Molecular Biology
Street address Campusvej 55
City Odense M
ZIP/Postal code 5230
Country Denmark
 
Platforms (1)
GPL11002 Illumina Genome Analyzer IIx (Mus musculus)
Samples (16)
GSM1199128 PPARγ ChIP-seq, 3T3-L1 Day7 1h DMSO rep1
GSM1199129 PPARγ ChIP-seq, 3T3-L1 Day7 1h Rosi rep1
GSM1199130 PPARγ ChIP-seq, 3T3-L1 Day7 1h DMSO rep2
Relations
BioProject PRJNA213884
SRA SRP028367

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE49423_CEBPa_peaks.txt.gz 759.5 Kb (ftp)(http) TXT
GSE49423_PPARg_Peaks.txt.gz 765.1 Kb (ftp)(http) TXT
GSE49423_RAW.tar 689.5 Mb (http)(custom) TAR (of BIGWIG)
SRA Run SelectorHelp
Processed data are available on Series record
Processed data provided as supplementary file
Raw data are available in SRA

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap